Evidence map›Paper›PMID 29907338›Full record

ReviewRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2018

Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation?

Reid F Thompson, Gilmer Valdes, Clifton D Fuller, Colin M Carpenter, Olivier Morin, Sanjay Aneja, William D Lindsay, Hugo J W L Aerts, Barbara Agrimson, Curtiland Deville and 3 more

Abstract readReview
In one paragraph

Review in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Reid F ThompsonOregon Health & Science University, Portland, USA; VA Portland Health Care System, Portland, USA. Electronic address: thompsre@ohsu.edu.
Gilmer ValdesUniversity of California San Francisco, San Francisco, USA.
Clifton D FullerMD Anderson Cancer Center, Houston, USA.
Colin M CarpenterSiris Medical, Inc, Redwood City, USA.
Olivier MorinUniversity of California San Francisco, San Francisco, USA.
Sanjay AnejaYale University, New Haven, USA.
William D LindsayOncora Medical, Philadelphia, USA.
Hugo J W L AertsBrigham and Women's Hospital, Boston, USA; Dana Farber Cancer Institute, Boston, USA.
Barbara AgrimsonOregon Health & Science University, Portland, USA.
Curtiland DevilleJohns Hopkins University School of Medicine, Baltimore, USA.
Seth A RosenthalSutter Medical Group and Suttter Cancer Center, Sacramento, USA.
James B YuYale University, New Haven, USA.
Charles R ThomasOregon Health & Science University, Portland, USA.

Funding

SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
QuBBD: Precision E –Radiomics for Dynamic Big Head & Neck Cancer Data R01CA225190 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$776k
NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA225190
6 · The paper itself

Abstract

Artificial intelligence (AI) is emerging as a technology with the power to transform established industries, and with applications from automated manufacturing to advertising and facial recognition to fully autonomous transportation. Advances in each of these domains have led some to call AI the "fourth" industrial revolution [1]. In healthcare, AI is emerging as both a productive and disruptive force across many disciplines. This is perhaps most evident in Diagnostic Radiology and Pathology, specialties largely built around the processing and complex interpretation of medical images, where the role of AI is increasingly seen as both a boon and a threat. In Radiation Oncology as well, AI seems poised to reshape the specialty in significant ways, though the impact of AI has been relatively limited at present, and may rightly seem more distant to many, given the predominantly interpersonal and complex interventional nature of the specialty. In this overview, we will explore the current state and anticipated future impact of AI on Radiation Oncology, in detail, focusing on key topics from multiple stakeholder perspectives, as well as the role our specialty may play in helping to shape the future of AI within the larger spectrum of medicine.

Indexed as

Artificial IntelligenceDecision Support TechniquesForecastingHumansMachine LearningPatient CareQuality Assurance, Health CareRadiation OncologyRadiologyRadiotherapy DosageArtificial intelligenceDeep learningMachine learning

Identifiers

PMID29907338
PMCPMC9620952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.